These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 20006376)
1. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376 [TBL] [Abstract][Full Text] [Related]
2. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797 [TBL] [Abstract][Full Text] [Related]
3. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211 [TBL] [Abstract][Full Text] [Related]
4. p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer. Seeger A; Kölbl H; Petry IB; Gebhard S; Battista MJ; Böhm D; Steiner E Gynecol Oncol; 2012 Apr; 125(1):200-7. PubMed ID: 22210468 [TBL] [Abstract][Full Text] [Related]
5. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma]. Xue F; Jiao S; Zhao F Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486 [TBL] [Abstract][Full Text] [Related]
6. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113 [TBL] [Abstract][Full Text] [Related]
7. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W Gynecol Oncol; 1999 Sep; 74(3):468-71. PubMed ID: 10479512 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Mitsudomi T; Hamajima N; Ogawa M; Takahashi T Clin Cancer Res; 2000 Oct; 6(10):4055-63. PubMed ID: 11051256 [TBL] [Abstract][Full Text] [Related]
9. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer. Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811 [TBL] [Abstract][Full Text] [Related]
10. p53 protein overexpression in early stage endometrial cancer. Kohlberger P; Gitsch G; Loesch A; Tempfer C; Kaider A; Reinthaller A; Kainz C; Breitenecker G Gynecol Oncol; 1996 Aug; 62(2):213-7. PubMed ID: 8751552 [TBL] [Abstract][Full Text] [Related]
12. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Laframboise S; Chapman W; McLaughlin J; Andrulis IL Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169 [TBL] [Abstract][Full Text] [Related]
13. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407 [TBL] [Abstract][Full Text] [Related]
14. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726 [TBL] [Abstract][Full Text] [Related]
15. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189 [TBL] [Abstract][Full Text] [Related]
16. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas. Segawa T; Sasagawa T; Saijoh K; Inoue M Clin Cancer Res; 2000 Jun; 6(6):2341-8. PubMed ID: 10873085 [TBL] [Abstract][Full Text] [Related]
18. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Salvesen HB; Das S; Akslen LA Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444 [TBL] [Abstract][Full Text] [Related]
19. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications. Shimizu K; Norimatsu Y; Kobayashi TK; Sakurai M; Ogura S; Yoshizawa A; Miyamoto T; Miyake Y; Aratake Y; Sakaguchi T; Ohno E Ann Diagn Pathol; 2009 Apr; 13(2):89-95. PubMed ID: 19302956 [TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Antonescu CR; Tschernyavsky SJ; Decuseara R; Leung DH; Woodruff JM; Brennan MF; Bridge JA; Neff JR; Goldblum JR; Ladanyi M Clin Cancer Res; 2001 Dec; 7(12):3977-87. PubMed ID: 11751490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]